A. Noujaim, B. Schultes, R. Baum, and R. Madiyalakan, Induction of CA125-Specific B and T Cell Responses in Patients Injected with MAb-B43.13???Evidence for Antibody-Mediated Antigen-Processing and Presentation of CA125 in Vivo, Cancer Biotherapy & Radiopharmaceuticals, vol.16, issue.3, pp.187-20310, 1089.
DOI : 10.1089/10849780152389384

A. Ladányi, J. Kiss, A. Mohos, B. Somlai, G. Liszkay et al., Prognostic impact of B-cell density in cutaneous melanoma, Cancer Immunology, Immunotherapy, vol.4, issue.12, pp.1729-1767, 2011.
DOI : 10.1371/journal.pone.0006412

J. Nielsen, R. Sahota, K. Milne, S. Kost, N. Nesslinger et al., CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27- Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer, Clinical Cancer Research, vol.18, issue.12, pp.3281-92, 2012.
DOI : 10.1158/1078-0432.CCR-12-0234
URL : http://clincancerres.aacrjournals.org/content/clincanres/18/12/3281.full.pdf

J. Shi, Q. Gao, Z. Wang, J. Zhou, X. Wang et al., Margin-Infiltrating CD20+ B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma, Clinical Cancer Research, vol.19, issue.21, pp.5994-6005, 2013.
DOI : 10.1158/1078-0432.CCR-12-3497

G. Bindea, B. Mlecnik, M. Tosolini, A. Kirilovsky, M. Waldner et al., Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer, Immunity, vol.39, issue.4, pp.782-95, 2013.
DOI : 10.1016/j.immuni.2013.10.003

A. Hennequin, V. Derangère, R. Boidot, L. Apetoh, J. Vincent et al., Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients, OncoImmunology, vol.30, issue.2, 2015.
DOI : 10.1093/bioinformatics/btp101
URL : https://hal.archives-ouvertes.fr/hal-01431846

D. Pinto, E. Montani, M. Bolli, G. Garavaglia, F. Sallusto et al., A functional BCR in human IgA and IgM plasma cells, Blood, vol.121, issue.20, pp.4110-4114, 2013.
DOI : 10.1182/blood-2012-09-459289

N. Pelletier, L. Mcheyzer-williams, K. Wong, E. Urich, N. Fazilleau et al., Plasma cells negatively regulate the follicular helper T cell program, Nature Immunology, vol.165, issue.12, pp.1110-1118, 1954.
DOI : 10.4049/jimmunol.0903505
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058870

T. Doi, T. Kanai, Y. Mikami, T. Sujino, L. Jun et al., IgA plasma cells express the negative regulatory co-stimulatory molecule programmed cell death 1 ligand and have a potential tolerogenic role in the intestine, Biochemical and Biophysical Research Communications, vol.425, issue.4, pp.918-941, 2012.
DOI : 10.1016/j.bbrc.2012.08.010

A. Khan, E. Hams, A. Floudas, T. Sparwasser, C. Weaver et al., PD-L1hi B cells are critical regulators of humoral immunity, Nature Communications, vol.286, 2015.
DOI : 10.1074/jbc.M110.188599
URL : http://doi.org/10.1038/ncomms6997

S. Finkin, D. Yuan, I. Stein, K. Taniguchi, A. Weber et al., Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma, Nature Immunology, vol.83, issue.12, pp.1235-1279, 2015.
DOI : 10.1021/ac202028g
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653079

J. Weber, J. Thompson, O. Hamid, D. Minor, A. Amin et al., A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma, Clinical Cancer Research, vol.15, issue.17, pp.5591-5599, 2009.
DOI : 10.1158/1078-0432.CCR-09-1024

J. Wolchok, B. Neyns, G. Linette, S. Negrier, J. Lutzky et al., Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study, The Lancet Oncology, vol.11, issue.2, pp.155-64, 2010.
DOI : 10.1016/S1470-2045(09)70334-1

O. Day, S. Maio, M. Chiarion-sileni, V. Gajewski, T. Pehamberger et al., Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study, Annals of Oncology, vol.21, issue.8, pp.1712-1719, 2010.
DOI : 10.1093/annonc/mdq013

M. Postow, J. Chesney, A. Pavlick, C. Robert, K. Grossmann et al., Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma, New England Journal of Medicine, vol.372, issue.21, pp.2006-2023, 2015.
DOI : 10.1056/NEJMoa1414428

S. Gettinger, L. Horn, L. Gandhi, D. Spigel, S. Antonia et al., Overall Survival and Long-Term Safety of Nivolumab (Anti???Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.33, issue.18, pp.2004-2016, 2015.
DOI : 10.1200/JCO.2014.58.3708

N. Rizvi, M. Hellmann, A. Snyder, P. Kvistborg, V. Makarov et al., Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, vol.105, issue.51, pp.124-132, 2015.
DOI : 10.1073/pnas.0810114105
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993154

E. Lutz, A. Wu, E. Bigelow, R. Sharma, G. Mo et al., Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation, Cancer Immunology Research, vol.2, issue.7, pp.616-647, 2014.
DOI : 10.1158/2326-6066.CIR-14-0027
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082460

L. Maldonado, J. Teague, M. Morrow, I. Jotova, T. Wu et al., Intramuscular Therapeutic Vaccination Targeting HPV16 Induces T Cell Responses That Localize in Mucosal Lesions, Science Translational Medicine, vol.12, issue.suppl_1, 2014.
DOI : 10.2307/1411
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086631

M. Dieu-nosjean, N. Giraldo, H. Kaplon, C. Germain, and W. Fridman, Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers, Immunological Reviews, vol.9, issue.Suppl 3, pp.260-75, 2016.
DOI : 10.1371/journal.pone.0099008